MedAvail Holdings, Inc.

NasdaqCM:MDVL Voorraadrapport

Marktkapitalisatie: US$2.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MedAvail Holdings Beheer

Beheer criteriumcontroles 1/4

De CEO MedAvail Holdings is Mark Doerr, benoemd in Jan2022, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.52M, bestaande uit 16.8% salaris en 83.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde $ 6.79K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 2.7 jaar.

Belangrijke informatie

Mark Doerr

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris16.80%
Dienstverband CEO2.1yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn2.4yrs
Gemiddelde ambtstermijn bestuur2.7yrs

Recente managementupdates

Recent updates

Analyse-artikel • Aug 17

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

MedAvail Holdings, Inc. ( NASDAQ:MDVL ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Aug 02

MedAvail Holdings: More Stock Dilution Seems Inevitable And I'm Bearish

MedAvail is a prescription drug-dispensing kiosks startup whose revenues are growing by over 100% year-on-year at the moment. However, the gross margin is barely positive and the operating loss expanded to $12.8 million in Q1 2022. Cash used in operational activities rose to $13.3 million in Q1 2022 and I think that the company will need another capital increase around the end of the year. However, short selling seems dangerous at the moment as the short borrow fee rate is almost 80%. Introduction I like writing about under covered stocks on SA, and today I'm taking a look at MedAvail Holdings (MDVL). It's a company focused on pharmacy automation kiosks and the growth of its business looks compelling. However, the operating expenses are high and the company is set to run low on cash again soon. I think that another stock dilution seems inevitable in the near future. Overall, I don't think that the business is worth much in its current state and I'm bearish. Let's review. Overview of the business and financials MedAvail is a pharmacy technology and services company whose main product is a MedCenter. This is a pharmacist controlled, customer-interactive, prescription dispensing system that looks somewhat like an ATM on the outside. MedAvail It's an interesting concept but there are several competitors with a similar business, including Omnicell (NASDAQ: OMCL) Dispension Industries, Pharmaself24. What MedAvail is offering doesn't seem to be unique. The company also operates full-service retail pharmacies under the SpotRx brand that use its automated pharmacy technology. MedAvail has bet on a hub and spoke model and it currently has operations in the states of Arizona, California, Michigan, and Florida. It plans to set foot in Texas and Illinois in the near future. MedAvail has partnered with several large brands, including IMA Medical Group, CareMore Health, Cigna (NYSE: CI), and Cano Health. MedAvail The dispensing units usually ramp up to $1 million in annual revenues by their second year. As of December 2021, MedAvail had a total of 13 dispensing units that were operating for over 18 months, and it plans to set up about 25-30 dispensing units in 2022. For the graphs below, note that net cumulative deployments exclude decommissioned clinics, pilot and demo sites. MedAvail MedAvail In Q1 2022, retail pharmacy and hardware revenues increased by 126.3% year-on-year thanks to a $5.4 million increase from volume growth in prescription revenue at existing sites as well as new sites in Florida and Michigan. Unfortunately, there don't appear to be significant economies of scale as the total cost of products sold and services soared by 132.3% to $8.61 million. In addition, operating expenses rose by 33.1% which led to a widening of the operating loss of MedAvail to $12.8 million in Q1 2022. MedAvail Looking at the future, the targeted milestones listed in MedAvail's latest corporate presentation include increasing the network of dispensing MedCenters to more than 100 in existing markets. I don't think this should be hard to achieve considering there were already 88 dispensing units in operation as of March 2022, up from 68 units in December 2021. The company also aims to reduce its quarterly cash burn by 20% by improving its gross margin and achieving greater hub pharmacy utilization. It also highlighted a procurement strategy for sourcing pharmaceuticals at optimal cost to drive utilization and the appropriate mix of medications. However, I don't see a path to profitability anytime soon considering the gross margin hasn't seen much improvement over the past few quarters and that the operating loss has increased by over 37% in just a year. In my view, this is a major issue as it has led to an increase of net cash used in operating activities to $13.3 million in Q1 2022, compared to $9.8 million a year earlier. As a result, MedAvail closed March with cash and cash equivalents of only $5.27 million. The company then raised $40 million through the issuance of 37.6 million shares at $1.0625 apiece in April 2022. Yet, I think that another large private placement is likely to take place around the end of 2022 due to the increase of cash used in operating activities. I think that more stock dilution seems inevitable at the moment. Turning our attention to the balance sheet, we can see that MedAvail has an asset-light business model and cash, receivables, and inventories accounted for almost half of the $27.7 million in total assets at the end of Q1 2022. I find it concerning that the accumulated deficit has surpassed $200 million. MedAvail Overall, I expect MedAvail to continue growing its revenues at a rapid pace and I think the annual run rate could surpass $50 million by the end of 2022. However, the gross margin is barely positive and when you add operating expenses, the picture isn't pretty. And with net cash used in operations growing rapidly, I think that another large capital increase is likely in a few months. I'm bearish but I don't think that this is a good time to be short selling MedAvail. According to data from Fintel, there are 250,000 shares available for borrowing as of the time of writing but the short borrow fee rate is 79.39%. And if you want to rely on put options instead, the lowest available strike price at the moment is $2.50.
Analyse-artikel • Aug 17

Some Analysts Just Cut Their MedAvail Holdings, Inc (NASDAQ:MDVL) Estimates

The latest analyst coverage could presage a bad day for MedAvail Holdings, Inc ( NASDAQ:MDVL ), with the analysts...
Analyse-artikel • May 24

Calculating The Intrinsic Value Of MedAvail Holdings, Inc (NASDAQ:MDVL)

Does the May share price for MedAvail Holdings, Inc ( NASDAQ:MDVL ) reflect what it's really worth? Today, we will...
Analyse-artikel • Feb 20

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

In this article we are going to estimate the intrinsic value of MedAvail Holdings, Inc ( NASDAQ:MDVL ) by taking the...

Analyse CEO-vergoeding

Hoe is Mark Doerr's beloning veranderd ten opzichte van MedAvail Holdings's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$55m

Dec 31 2022US$3mUS$424k

-US$48m

Compensatie versus markt: De totale vergoeding ($USD 2.52M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 672.31K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Mark te vergelijken met de prestaties van het bedrijf.

CEO

Mark Doerr (53 yo)

2.1yrs
Tenure
US$2,524,419
Compensatie

Mr. Mark Doerr, RPh serves as Chief Executive Officer, President and Director at MedAvail Holdings, Inc since January 10, 2022. He serves as the Chief Executive Officer of eRx Network, LLC since March 28,...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mark Doerr
CEO, President & Director2.1yrsUS$2.52m0.23%
$ 6.8k
Ramona Seabaugh
CFO, Treasurer & Secretary2.4yrsUS$537.22k0.076%
$ 2.2k
Emilia Keric
Senior VP & General Counselless than a yeargeen gegevensgeen gegevens
Joan O'Rourke
President of SpotRx2.8yrsgeen gegevensgeen gegevens
Brian Schlerf
Corporate Controller3.1yrsgeen gegevensgeen gegevens
2.4yrs
Gemiddelde duur

Ervaren management: Het managementteam van MDVL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Mark Doerr
CEO, President & Director2.1yrsUS$2.52m0.23%
$ 6.8k
Robert Faulkner
Chairman of the Board3.3yrsgeen gegevens0.12%
$ 3.6k
Laurie McGraw
Independent Director2.1yrsUS$217.96k0%
$ 0
Michael Kramer
Independent Director3.3yrsUS$187.00k0%
$ 0
Glen Stettin
Independent Director3.3yrsUS$170.00k0%
$ 0
Paul Johnson
Independent Director2.1yrsUS$224.96k0%
$ 0
2.7yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MDVL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/02/03 11:10
Aandelenkoers aan het einde van de dag2024/02/02 00:00
Inkomsten2023/06/30
Jaarlijkse inkomsten2022/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

MedAvail Holdings, Inc. wordt gevolgd door 2 analisten. van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Brooks O'NeilLake Street Capital Markets, LLC
Charles RhyeeTD Cowen